Alluvi, previously BI 4744, presents a promising advance in weight management care. This dual activator targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable results in clinical trials, possibly https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/